|
1
|
Antibody targeting of long-circulating lipidic nanoparticles does not increase tumor localization but does increase internalization in animal models.
|
Cancer Res
|
2006
|
4.43
|
|
2
|
Distribution of liposomes into brain and rat brain tumor models by convection-enhanced delivery monitored with magnetic resonance imaging.
|
Cancer Res
|
2004
|
2.10
|
|
3
|
Gadolinium-loaded liposomes allow for real-time magnetic resonance imaging of convection-enhanced delivery in the primate brain.
|
Exp Neurol
|
2005
|
1.78
|
|
4
|
Extensive distribution of liposomes in rodent brains and brain tumors following convection-enhanced delivery.
|
J Neurooncol
|
2004
|
1.61
|
|
5
|
Epidermal growth factor receptor-targeted immunoliposomes significantly enhance the efficacy of multiple anticancer drugs in vivo.
|
Cancer Res
|
2005
|
1.51
|
|
6
|
Development of ligand-targeted liposomes for cancer therapy.
|
Expert Opin Ther Targets
|
2004
|
1.48
|
|
7
|
Impact of single-chain Fv antibody fragment affinity on nanoparticle targeting of epidermal growth factor receptor-expressing tumor cells.
|
J Mol Biol
|
2007
|
1.48
|
|
8
|
Characterization of biofilm formation by clinical isolates of Mycobacterium avium.
|
J Med Microbiol
|
2003
|
1.45
|
|
9
|
Novel nanoliposomal CPT-11 infused by convection-enhanced delivery in intracranial tumors: pharmacology and efficacy.
|
Cancer Res
|
2006
|
1.36
|
|
10
|
Targeted tumor cell internalization and imaging of multifunctional quantum dot-conjugated immunoliposomes in vitro and in vivo.
|
Nano Lett
|
2008
|
1.34
|
|
11
|
Epidermal growth factor receptor (EGFR)-targeted immunoliposomes mediate specific and efficient drug delivery to EGFR- and EGFRvIII-overexpressing tumor cells.
|
Cancer Res
|
2003
|
1.33
|
|
12
|
Convection-enhanced delivery of Ls-TPT enables an effective, continuous, low-dose chemotherapy against malignant glioma xenograft model.
|
Neuro Oncol
|
2006
|
1.29
|
|
13
|
Liposome-based approaches to overcome anticancer drug resistance.
|
Drug Resist Updat
|
2003
|
1.27
|
|
14
|
Convection-enhanced delivery of a topoisomerase I inhibitor (nanoliposomal topotecan) and a topoisomerase II inhibitor (pegylated liposomal doxorubicin) in intracranial brain tumor xenografts.
|
Neuro Oncol
|
2006
|
1.26
|
|
15
|
Anti-CD166 single chain antibody-mediated intracellular delivery of liposomal drugs to prostate cancer cells.
|
Mol Cancer Ther
|
2007
|
1.22
|
|
16
|
Tissue affinity of the infusate affects the distribution volume during convection-enhanced delivery into rodent brains: implications for local drug delivery.
|
J Neurosci Methods
|
2006
|
1.17
|
|
17
|
Identification and characterization of tumor antigens by using antibody phage display and intrabody strategies.
|
Mol Immunol
|
2007
|
1.07
|
|
18
|
Preclinical manufacture of anti-HER2 liposome-inserting, scFv-PEG-lipid conjugate. 2. Conjugate micelle identity, purity, stability, and potency analysis.
|
Biotechnol Prog
|
2005
|
1.06
|
|
19
|
Targeted drug delivery to mesothelioma cells using functionally selected internalizing human single-chain antibodies.
|
Mol Cancer Ther
|
2008
|
1.04
|
|
20
|
Phosphatidylserine binding alters the conformation and specifically enhances the cofactor activity of bovine factor Va.
|
Biochemistry
|
2002
|
1.00
|
|
21
|
Recombinant full-length human IgG1s targeting hormone-refractory prostate cancer.
|
J Mol Med (Berl)
|
2007
|
0.99
|
|
22
|
Preclinical manufacture of an anti-HER2 scFv-PEG-DSPE, liposome-inserting conjugate. 1. Gram-scale production and purification.
|
Biotechnol Prog
|
2005
|
0.98
|
|
23
|
Canine spontaneous glioma: a translational model system for convection-enhanced delivery.
|
Neuro Oncol
|
2010
|
0.97
|
|
24
|
HER2-targeted liposomal doxorubicin displays enhanced anti-tumorigenic effects without associated cardiotoxicity.
|
Toxicol Appl Pharmacol
|
2012
|
0.96
|
|
25
|
A novel assay for monitoring internalization of nanocarrier coupled antibodies.
|
BMC Immunol
|
2006
|
0.95
|
|
26
|
Specificity of soluble phospholipid binding sites on human factor Xa.
|
Biochemistry
|
2002
|
0.95
|
|
27
|
Characterization of highly stable liposomal and immunoliposomal formulations of vincristine and vinblastine.
|
Cancer Chemother Pharmacol
|
2009
|
0.95
|
|
28
|
Comparing routes of delivery for nanoliposomal irinotecan shows superior anti-tumor activity of local administration in treating intracranial glioblastoma xenografts.
|
Neuro Oncol
|
2012
|
0.92
|
|
29
|
Investigation of intravenous delivery of nanoliposomal topotecan for activity against orthotopic glioblastoma xenografts.
|
Neuro Oncol
|
2011
|
0.83
|
|
30
|
Building and characterizing antibody-targeted lipidic nanotherapeutics.
|
Methods Enzymol
|
2012
|
0.79
|
|
31
|
Comprehensive optimization of a single-chain variable domain antibody fragment as a targeting ligand for a cytotoxic nanoparticle.
|
MAbs
|
2015
|
0.78
|
|
32
|
Pharmacokinetics, tumor accumulation and antitumor activity of nanoliposomal irinotecan following systemic treatment of intracranial tumors.
|
Nanomedicine (Lond)
|
2014
|
0.76
|
|
33
|
Convection-enhanced delivery of targeted quantum dot-immunoliposome hybrid nanoparticles to intracranial brain tumor models.
|
Nanomedicine (Lond)
|
2013
|
0.75
|
|
34
|
Extended topoisomerase 1 inhibition through liposomal irinotecan results in improved efficacy over topotecan and irinotecan in models of small-cell lung cancer.
|
Anticancer Drugs
|
2017
|
0.75
|